Veracyte, Inc.
43.86USD
+1.4100 (+3.32%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.41▼ | $0.43 | 0 | 9 |
| Next quarter | $0.45▼ | $0.45 | 4 | 5 |
| Current year | $1.91▲ | $1.82 | 10 | 0 |
| Next year | $1.95▲ | $1.91 | 7 | 3 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.43 | $0.54 | +0.11 (+25.1%) |
| 2026-03-31 | $0.33 | $0.52 | +0.19 (+56.0%) |
| 2025-12-31 | $0.41 | $0.53 | +0.12 (+29.8%) |
| 2025-09-30 | $0.32 | $0.51 | +0.19 (+59.5%) |
117 ratings from 21 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | Maintained | Buy | $52 $65 | Sep 9, 2026 |
| Piper Sandler | Maintained | Overweight | $66 $54 | Aug 4, 2026 |
| Stephens & Co. | Maintained | Overweight | $68 $55 | Aug 4, 2026 |
| Morgan Stanley | Maintained | Underweight | $47 $44 | Aug 4, 2026 |
| Canaccord Genuity | Maintained | Hold | $60 $50 | Aug 3, 2026 |
| Needham | Maintained | Buy | $57 $69 | Jul 31, 2026 |
| Needham | Maintained | Buy | $57 $69 | Jul 30, 2026 |
| Piper Sandler | Initiated | Overweight | $66 | Jul 15, 2026 |
| Canaccord Genuity | Maintained | Hold | $42 $60 | Jul 14, 2026 |
| Morgan Stanley | Maintained | Underweight | $37 $47 | Jul 9, 2026 |
| Guggenheim | Maintained | Buy | $45 $65 | Jun 29, 2026 |
| Needham | Maintained | Buy | $48 $57 | Jun 1, 2026 |
| Needham | Reiterated | Buy | $48 | May 28, 2026 |
| Canaccord Genuity | Maintained | Hold | $40 $42 | May 6, 2026 |
| UBS | Maintained | Buy | $48 $52 | May 6, 2026 |
| Canaccord Genuity | Maintained | Hold | $43 $40 | Apr 20, 2026 |
| Jefferies | Initiated | Buy | $45 | Apr 13, 2026 |
| Needham | Maintained | Buy | $48 | Apr 1, 2026 |
| Guggenheim | Maintained | Buy | $50 $45 | Mar 30, 2026 |
| Morgan Stanley | Maintained | Underweight | $48 $37 | Mar 6, 2026 |
| Needham | Maintained | Buy | $44 $48 | Feb 26, 2026 |
| Guggenheim | Maintained | Buy | $45 $50 | Jan 5, 2026 |
| Morgan Stanley | Maintained | Underweight | $40 $48 | Dec 2, 2025 |
| Morgan Stanley | Maintained | Underweight | $28 $40 | Nov 11, 2025 |
| UBS | Maintained | Buy | $42 $48 | Nov 5, 2025 |
118 filings from 22 insiders · 17 buy / 12 sell over 6m
Officers and directors of VCYT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McGuire AnnieOfficer, EVP, General Counsel | Sell | 1.1k | $43.67 | $48k | Sep 4, 2026 |
| McGuire AnnieOfficer, EVP, General Counsel | Sell | 2.2k | $42.79 | $92k | Sep 4, 2026 |
| Chambers RebeccaOfficer, Chief Financial Officer | Sell | 1.2k | $43.71 | $51k | Sep 4, 2026 |
| Chambers RebeccaOfficer, Chief Financial Officer | Sell | 2.5k | $42.81 | $106k | Sep 4, 2026 |
| Febbo Phillip G.Officer, Chief Scientific & Med Officer | Sell | 2.7k | $43.66 | $118k | Sep 4, 2026 |
| Febbo Phillip G.Officer, Chief Scientific & Med Officer | Sell | 10.4k | $42.89 | $446k | Sep 4, 2026 |
| Leite JohnOfficer, Global Chief Commercial Off | Tax | 4.0k | $44.88 | $178k | Sep 2, 2026 |
| McGuire AnnieOfficer, EVP, General Counsel | Tax | 3.2k | $44.88 | $144k | Sep 2, 2026 |
| Chambers RebeccaOfficer, Chief Financial Officer | Tax | 3.6k | $44.88 | $162k | Sep 2, 2026 |
| Febbo Phillip G.Officer, Chief Scientific & Med Officer | Tax | 3.6k | $44.88 | $163k | Sep 2, 2026 |
| Wygant JonathanOfficer, VP, Chief Accounting Officer | Tax | 1.4k | $44.88 | $61k | Sep 2, 2026 |
| Stapley MarcDirector; Officer, Chief Executive Officer | Tax | 8.8k | $44.88 | $394k | Sep 2, 2026 |
| Bhanji MunaDirector | Sell | 1.9k | $42.97 | $80k | Sep 1, 2026 |
| EASTHAM KARINDirector | Sell | 3.7k | $52.78 | $197k | Jun 18, 2026 |
| EASTHAM KARINDirector | Grant | 5.3k | — | — | Jun 11, 2026 |
| JONES EVANDirector | Grant | 5.3k | — | — | Jun 11, 2026 |
| EPSTEIN ROBERT SDirector | Grant | 5.3k | — | — | Jun 11, 2026 |
| SHAFER DAVID BRENTDirector | Grant | 5.3k | — | — | Jun 11, 2026 |
| HOLSTEIN JENSDirector | Grant | 5.3k | — | — | Jun 11, 2026 |
| BHANJI MUNADirector | Grant | 5.3k | — | — | Jun 11, 2026 |
No analyst notes on VCYT yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 8 | 1 | 1 | 0 | Buy2.08 |
| 1 mo ago | 2 | 7 | 1 | 1 | 0 | Buy2.09 |
| 2 mo ago | 1 | 8 | 1 | 1 | 0 | Buy2.18 |